SCHEMBL21773134

SCHEMBL21773134

Cc1nc(S(=O)(=O)N(C(=O)O)c2cscn2)ccc1N(C)[C@H]1CCNC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN1A P35498 10/20 0.41
SCN8A Q9UQD0 10/20 0.41
SLC6A4 P31645 2/20 0.33
SLC6A2 P23975 1/20 0.33
CHEK2 O96017 1/20 0.32
KCNH2 Q12809 2/20 0.31
CHEK1 O14757 1/20 0.31
RPLP1 P05386 1/20 0.30
RPLP0 P05388 1/20 0.30
RPS17 P08708 1/20 0.30
RPSA P08865 1/20 0.30
RPS2 P15880 1/20 0.30
RPL35A P18077 1/20 0.30
RPL7 P18124 1/20 0.30
RPL17 P18621 1/20 0.30
RPS4Y1 P22090 1/20 0.30
RPS3 P23396 1/20 0.30
RPS12 P25398 1/20 0.30
RPL13 P26373 1/20 0.30
RPL10 P27635 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21773165 0.85 SCN8A (0.42) SCN1ASCN8A
SCHEMBL21772996 0.78 SCN8A (0.69) SCN1ASCN8A
SCHEMBL21789061 0.77 SCN8A (0.43) SCN1ASCN8ASLC6A4SLC6A2KCNH2
Formic Acid SCHEMBL30845609 0.76 SCN8A (0.57) SCN1ASCN8A
Formic Acid SCHEMBL28564571 0.76 SCN8A (0.57) SCN1ASCN8A
Formic Acid SCHEMBL21773131 0.76 SCN8A (0.57) SCN1ASCN8A
SCHEMBL21773121 0.75 NPC1 (0.32) SCN1ASCN8A
SCHEMBL21777202 0.75 SCN8A (0.35) SCN1ASCN8A
SCHEMBL28559498 0.69 SCN8A (0.37) SCN1ASCN8A
SCHEMBL19613601 0.67 SCN8A (0.42) SCN1ASCN8A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10752623-B2 Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors XENON PHARMACEUTICALS INC. (CA) 2020-08-25 US disclosed
US-20200071313-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2020-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200071313-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS SCN1A, SCN2A, SCN2B SCN1A 1/4885SCN8A 6/4885SLC6A4 121/4885
US-10752623-B2 Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors SCN1A, SCN2A, SCN2B SCN1A 1/4885SCN8A 6/4885SLC6A4 121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.